Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.66 |
| ▸ | GLP1R | P43220 | 10/20 | 0.63 |
| ▸ | ECE1 | P42892 | 1/20 | 0.63 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.63 |
| ▸ | NPBWR1 | P48145 | 5/20 | 0.63 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.59 |
| ▸ | CCKBR | P32239 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30076208 | 0.97 | GLP1R (0.63) | RXFP1GLP1RECE1MUS81NPBWR1 | |
| SCHEMBL30220493 | 0.97 | RXFP1 (0.65) | RXFP1GLP1RECE1MUS81NPBWR1 | |
| SCHEMBL30598132 | 0.96 | RXFP1 (0.64) | RXFP1GLP1RECE1MUS81NPBWR1 | |
| SCHEMBL31087271 | 0.95 | RXFP1 (0.68) | RXFP1GLP1RECE1MUS81NPBWR1 | |
| SCHEMBL30271994 | 0.95 | RXFP1 (0.68) | RXFP1GLP1RECE1MUS81NPBWR1 | |
| SCHEMBL30874400 | 0.94 | RXFP1 (0.62) | RXFP1GLP1RECE1MUS81NPBWR1 | |
| SCHEMBL31759108 | 0.94 | RXFP1 (0.67) | RXFP1GLP1RECE1MUS81NPBWR1 | |
| SCHEMBL29462132 | 0.94 | RXFP1 (0.70) | RXFP1GLP1RECE1MUS81PTH1R | |
| SCHEMBL30183270 | 0.94 | RXFP1 (0.70) | RXFP1GLP1RECE1MUS81PTH1R | |
| SCHEMBL30635326 | 0.94 | RXFP1 (0.70) | RXFP1GLP1RECE1MUS81PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452049-B1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS INC (US) | 2026-04-01 | — | — | EP | claimed |
| US-20230346949-A1 | A METHOD OF FORMING A CONJUGATE OF A SULFONAMIDE AND A POLYPEPTIDE | SANOFI SA (FR) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346949-A1 | A METHOD OF FORMING A CONJUGATE OF A SULFONAMIDE AND A POLYPEPTIDE | IAPP, AMY2A, STS | RXFP1 2208/4885GLP1R 28/4885ECE1 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.